Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Teriparatide (SAL001) vs Forsteo in Healthy Chinese Volunteers
NCT04747392Phase 1Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of teriparatide in postmenopausal osteoporosis (2 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t at Day 4 and Peak Plasma Concentration at Day 4. Started Aug 2020; status: completed.
02
Drugs
teriparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04747392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747392.